Infinity Pharmaceuticals | INFI - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Alterity Therapeutics Limited AUD 27.32M 6.07M 2023-06
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Cipla INR 401.64B 27.77B 2025-09
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 156.57M 58.73M 2025-12
CSL USD 37.9B 1.5B 2025-12
Eisai JPY 1.49T 48.22B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Grifols EUR 23.15B 142.7M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Infinity Pharmaceuticals USD 21.23M 8.72M 2023-06
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
J&J USD 199.21B 6.39B 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Plus Therapeutics USD 11.39M 1.89M 2023-12
Roche Holding CHF 100.7B 5.94B 2025-12
TG Therapeutics USD 1.06B 38.23M 2025-12